SAB Biotherapeutics, Inc. develops fully human anti-thymocyte immunoglobulin and multi-specific human immunoglobulin G therapies for type 1 diabetes and other autoimmune diseases. Its lead program, SAB-142, is a disease-focused immunotherapy candidate for autoimmune type 1 diabetes, supported by the company’s transchromosomic cattle, or Tc-Bovine, production system for generating targeted hIgG antibodies.
Recurring news themes include SAB-142 clinical and mechanistic data, scientific conference presentations, financial results and business updates, and capital actions such as common stock and pre-funded warrant offerings that fund clinical development, manufacturing, regulatory activity and general corporate purposes.
SAB Biotherapeutics announced the completion of its business combination with Big Cypress Acquisition Corp., with shares commencing trading on Nasdaq under the ticker symbols SABS and SABSW on October 25, 2021. The transaction received approval from both companies' shareholders, resulting in gross proceeds of approximately $30 million. SAB aims to utilize these funds to advance its clinical programs, including those related to COVID-19 and influenza, and has secured an additional $60.5 million government award. SAB is focused on developing its unique DiversitAb™ immunotherapy platform.